The most revealing thing GSK did this decade was decide what it no longer wanted to be. In July 2022, the British company separated Haleon, the consumer-health business stocked with Sensodyne toothpaste, Advil painkillers and other household brands. Out went the bathroom cabinet. What remained was a more concentrated proposition: vaccines to prevent disease, specialty medicines to alter its course and a broad shelf of general medicines to serve primary care and help finance the next wave.
This is still an enormous machine. GSK reported £32.7 billion in 2025 turnover, employed 66,800 people across about 70 countries and supplied more than 2 billion packs of medicine and vaccine doses. But its strategic story has become easier to draw. The company studies the immune system, combines that knowledge with genetics and advanced technology, and applies it in four areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.
Three engines, different jobs
GSK is best understood as three businesses that share laboratories, factories, regulatory expertise and sales infrastructure. Specialty Medicines was the largest in 2025, producing £13.5 billion in turnover and growing fastest. It includes treatments such as Nucala for eosinophil-driven disease, Benlysta for lupus, oncology medicines including Jemperli and the HIV portfolio developed by majority-owned ViiV Healthcare.
Vaccines produced £9.2 billion. Shingrix protects against shingles. Arexvy addresses respiratory syncytial virus in eligible adults. Bexsero and Penmenvy target meningococcal disease. This business is difficult to duplicate because a vaccine is more than its antigen. Adjuvant systems, clinical evidence, sterile manufacturing, quality control, public-health recommendations and dependable distribution all matter. A discovery that cannot be produced by the hundred million is not yet a global product.
General Medicines delivered £10 billion, led by respiratory treatments and established products. Trelegy Ellipta compresses three inhaled medicines into a once-daily therapy for COPD and certain asthma patients; Ventolin is familiar across generations. These older and often more competitive products are less glamorous than a new biologic. They are also used by millions, give GSK reach in primary care and produce cash that can be placed back into research.
“The immune system is not one market. It is the thread connecting a shingles shot, an asthma biologic, a lupus therapy and a cancer drug.”A practical reading of GSK's portfolio
The customer is a chain
A patient swallows the tablet or receives the injection, but pharmaceutical customers do not resemble ordinary shoppers. A physician may select the treatment. A regulator decides whether it can be sold. An insurer or national health service negotiates what it will pay. A hospital, pharmacy or wholesaler places the order. Governments and international organisations buy vaccines for public programmes. The patient is the beneficiary at the end of a chain of evidence, permission, reimbursement and logistics.
That chain explains the problems GSK actually solves. The obvious ones are clinical: preventing shingles or RSV, controlling severe asthma, suppressing HIV, treating lupus, fighting bacterial infection and improving outcomes in cancer. The less visible problems are operational. Trials must show that benefits outweigh risks. A factory must repeat a delicate biological process. Supply must arrive when a vaccination season begins. Evidence must make sense to agencies with different rules and health systems with different budgets.
The business model follows that route. GSK spends heavily before it knows whether an asset will work - £7.5 billion on R&D in 2025 - then seeks patents, approvals and reimbursement. Successful products must repay the cost of their own development, the candidates that failed and the manufacturing network behind them. When patents expire, generic or biosimilar competition can compress sales. The pipeline is therefore less a trophy case than a replacement system.
A specialist hiding inside a giant
ViiV Healthcare is the clearest example of how GSK tries to behave like a specialist without surrendering the scale of a multinational. GSK created ViiV with Pfizer in 2009; Shionogi joined as a shareholder in 2012. The company focuses solely on HIV, with a portfolio built around integrase inhibitors that block an enzyme the virus needs to replicate.
Its more interesting design question is not simply which molecule works, but how often a person must think about treatment. Daily medication may expose someone to stigma, be inconvenient or simply be hard to sustain. Cabenuva, a long-acting injectable regimen, turned dosing frequency into a feature. ViiV's pipeline is exploring still longer intervals, including twice-yearly possibilities. In medicine, reducing the number of moments a treatment intrudes on a life can be a form of innovation.
Where GSK is unusually GSK
The company competes with nearly every large drugmaker somewhere. Sanofi, Pfizer and Merck meet it in vaccines. Gilead is a formidable HIV rival. AstraZeneca and Boehringer Ingelheim contest respiratory markets. Oncology is crowded with Roche, Merck, Bristol Myers Squibb, AstraZeneca and dozens of focused biotechs. GSK's distinction is not an absence of alternatives. It is the combined weight of vaccines, respiratory science and a dedicated HIV company, tied together by immune biology and backed by global manufacturing.
That combination also creates useful balance. Vaccines can reach large populations before illness appears. Specialty drugs serve narrower groups with higher unmet need and often higher prices. General medicines offer volume and established demand. A small biotech may move faster around one target; GSK can fund trials, navigate regulators, manufacture and distribute across continents. Its burden is the reverse: keeping a vast organisation decisive enough to benefit from the science it finds.
“No single scientist, nor any one technology, can keep us ahead of disease.”GSK on its partnership strategy
Buying time in oncology
In July 2026, GSK completed the $10.6 billion acquisition of Nuvalent, a Boston biotech specialising in precisely targeted cancer therapies. The purchase added three lung-cancer assets. Two late-stage medicines target ROS1-positive and ALK-altered non-small cell lung cancer, genetic subsets where resistance, side effects and brain metastases complicate existing treatment. One of those medicines, zidesamtinib, soon received US approval under the brand Jideytro for previously treated ROS1-positive disease.
The deal says two things. First, GSK wants to expand beyond its positions in blood and gynaecological cancers into lung and other solid tumours. Second, it is willing to pay heavily for validated targets and late-stage evidence rather than wait for every programme to emerge from its own laboratories. Partnerships with Oxford, Muna Therapeutics, Relation Therapeutics and Wave Life Sciences follow the same logic at earlier stages: useful science does not respect corporate walls.
Scale with a public-health shadow
Drugmakers operate under a tension that consumer companies rarely face so directly. A medicine can be scientifically valuable and commercially inaccessible. GSK says it aims to improve the health of 2.5 billion people by the end of 2030. In 2025 it delivered 99 million doses of critical vaccines to Gavi for lower-income countries and ranked second in the Access to Medicine Index. Those numbers are meaningful, but they also underline the size of the obligation. Pricing, supply, licensing and local delivery determine whether an approved product becomes a health outcome.
Inside the company, the stated culture is compact: be ambitious for patients, accountable for impact and do the right thing. Employee engagement has remained above 80 percent for three years. The phrases are simple enough to fit on a wall; the test is what happens when trial speed, quarterly performance, safety, access and cost pull in different directions. In a regulated business, culture is partly the quality of the decisions made when nobody gets everything they want.
The long experiment
GSK officially dates to the 2000 merger of Glaxo Wellcome and SmithKline Beecham, but its family tree wanders back to a London pharmacy opened in 1715 and a dried-milk product that adopted the Glaxo name in 1906. The history is full of combinations. The present strategy is a subtraction: fewer categories, a clearer scientific centre and more capital aimed at vaccines and specialty medicine.
Its 58-asset pipeline contained 17 programmes in phase III or registration at the end of 2025. Five major approvals arrived that year. Those figures are neither guarantees nor decoration. They are a portfolio of expensive probabilities. Some candidates will fail, some will arrive late and a few may alter standards of care. GSK's advantage is that it can run many of those experiments at once. Its challenge is ensuring that scale produces choices rather than inertia.
The consumer-health split made the scorecard less forgiving. There is no toothpaste growth to soften a weak drug launch. Investors can now look directly at vaccines, specialty medicines, general medicines and the pipeline meant to renew them. Patients see something else: a shingles appointment, an inhaler, an injection that replaces a daily pill. Between those views sits GSK, trying to turn immune science into products that work, factories that repeat and systems that can afford to use them.